Login to Site User Name   Password   Remember me next time or

U.S. Food And Drug Administration Approves Cayston(R) For The Improvement Of Respiratory Symptoms In Cystic Fibrosis PatientsGilead Sciences, Inc. (Nasdaq:GILD) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa)...

Aradigm Doses First Patient In Its Second Phase 2b Clinical Trial Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis PatientsAradigm Corporation (OTCBB:ARDM) (the "Company") announced that it dosed the first patient in the U.S...

PARI Pharma's Altera Delivers Gilead's Cayston, Approved By The U.S. FDA For The Improvement Of Respiratory Symptoms In Cystic Fibrosis PatientsAltera, which uses eFlow Technology, was cleared to market by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston (aztreonam for inhalation solution) 75 mg. Cayston is a new inhaled antibiotic that received marketing approval from the U.S...

Cached at: 3/14/2010 4:58:50 PM